Detalles de la búsqueda
1.
Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors.
J Cancer Res Clin Oncol
; 149(9): 6247-6262, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-36707445
2.
Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2- advanced breast cancer: a matching-adjusted indirect comparison.
Ther Adv Med Oncol
; 15: 17588359231152843, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36861085
3.
Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial.
Leukemia
; 37(5): 1060-1067, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37069326
4.
Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in Italy.
Pharmacoecon Open
; 6(1): 95-104, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34297312
5.
Enabling access to molecular monitoring for chronic myeloid leukemia patients is cost effective in China.
PLoS One
; 16(10): e0259076, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34695169
6.
Impact of prophylactic vaccination strategies on Ebola virus transmission: A modeling analysis.
PLoS One
; 15(4): e0230406, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32339195
7.
Reduced Diabetes Mellitus-related Comorbidities by Regular Self-monitoring of Blood Glucose: Economic and Quality of Life Implications.
Indian J Endocrinol Metab
; 22(4): 461-465, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30148089
Resultados
1 -
7
de 7
1
Próxima >
>>